SG11202002528SA - Radioactive drug - Google Patents
Radioactive drugInfo
- Publication number
- SG11202002528SA SG11202002528SA SG11202002528SA SG11202002528SA SG11202002528SA SG 11202002528S A SG11202002528S A SG 11202002528SA SG 11202002528S A SG11202002528S A SG 11202002528SA SG 11202002528S A SG11202002528S A SG 11202002528SA SG 11202002528S A SG11202002528S A SG 11202002528SA
- Authority
- SG
- Singapore
- Prior art keywords
- radioactive drug
- radioactive
- drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017185484 | 2017-09-26 | ||
| PCT/JP2018/035786 WO2019065774A1 (ja) | 2017-09-26 | 2018-09-26 | 放射性薬剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002528SA true SG11202002528SA (en) | 2020-04-29 |
Family
ID=65903027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002528SA SG11202002528SA (en) | 2017-09-26 | 2018-09-26 | Radioactive drug |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11167050B2 (ja) |
| EP (1) | EP3689892B1 (ja) |
| JP (1) | JP7207740B2 (ja) |
| KR (1) | KR20200056979A (ja) |
| CN (1) | CN111065646B (ja) |
| CA (1) | CA3086454A1 (ja) |
| SG (1) | SG11202002528SA (ja) |
| WO (1) | WO2019065774A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3043816A1 (en) | 2016-11-18 | 2018-05-24 | Astellas Pharma Inc. | Novel anti-human muc1 antibody fab fragment |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| CA3097101A1 (en) * | 2018-04-16 | 2019-10-24 | Nihon Medi-Physics Co., Ltd. | Modified antibody and radioactive metal-labelled antibody |
| TWI835880B (zh) | 2018-10-10 | 2024-03-21 | 日商安斯泰來製藥股份有限公司 | 含有標識部－抗人類抗體Ｆａｂ片段複合體之醫藥組成物 |
| US11919972B2 (en) | 2018-11-02 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Peptide libraries with non-canonical amino acids |
| JPWO2020145228A1 (ja) | 2019-01-07 | 2021-11-11 | アステラス製薬株式会社 | 配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体 |
| AU2021230210A1 (en) | 2020-03-04 | 2022-09-22 | Kyoto University | Compound and radioactive labeling compound |
| WO2022098745A1 (en) * | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
| US20240174622A1 (en) | 2021-03-04 | 2024-05-30 | Nihon Medi-Physics Co., Ltd. | Compound and radioactive labeling compound |
| CN118382464A (zh) | 2021-11-30 | 2024-07-23 | 日本医事物理股份有限公司 | 稳定化放射性药物组合物 |
| CN114685389B (zh) * | 2022-03-04 | 2023-10-27 | 复旦大学附属中山医院 | 一种基于迈克尔加成的pet显像剂、制备方法与用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005047821A (ja) * | 2003-07-30 | 2005-02-24 | Nihon Medi Physics Co Ltd | シクロペンタジエニルカルボニル基を含む放射性化合物を用いた診断及び治療用薬剤 |
| WO2013081091A1 (ja) | 2011-12-01 | 2013-06-06 | 国立大学法人 千葉大学 | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 |
| JP6410339B2 (ja) * | 2013-03-25 | 2018-10-24 | 国立大学法人千葉大学 | 放射性核種標識オクトレオチド誘導体 |
| CN108699108B (zh) | 2016-03-01 | 2022-04-08 | 国立大学法人千叶大学 | 放射性标记药物 |
-
2018
- 2018-09-26 EP EP18861877.1A patent/EP3689892B1/en active Active
- 2018-09-26 WO PCT/JP2018/035786 patent/WO2019065774A1/ja unknown
- 2018-09-26 CN CN201880055323.7A patent/CN111065646B/zh active Active
- 2018-09-26 US US16/648,703 patent/US11167050B2/en active Active
- 2018-09-26 SG SG11202002528SA patent/SG11202002528SA/en unknown
- 2018-09-26 CA CA3086454A patent/CA3086454A1/en active Pending
- 2018-09-26 KR KR1020207003700A patent/KR20200056979A/ko not_active Application Discontinuation
- 2018-09-26 JP JP2019545585A patent/JP7207740B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200268913A1 (en) | 2020-08-27 |
| JP7207740B2 (ja) | 2023-01-18 |
| CN111065646A (zh) | 2020-04-24 |
| WO2019065774A1 (ja) | 2019-04-04 |
| JPWO2019065774A1 (ja) | 2021-01-28 |
| CA3086454A1 (en) | 2019-04-04 |
| CN111065646B (zh) | 2023-05-30 |
| US11167050B2 (en) | 2021-11-09 |
| EP3689892A1 (en) | 2020-08-05 |
| EP3689892B1 (en) | 2024-07-17 |
| EP3689892A4 (en) | 2021-05-12 |
| KR20200056979A (ko) | 2020-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL266017A (en) | Pharmaceutical compounds | |
| SG11202002528SA (en) | Radioactive drug | |
| GB201612092D0 (en) | Pharmaceutical compounds | |
| GB201617758D0 (en) | Pharmaceutical compounds | |
| IL264415B (en) | A pharmaceutical compound | |
| GB201709652D0 (en) | Pharmaceutical compounds | |
| GB201704965D0 (en) | Pharmaceutical compounds | |
| HUE052107T2 (hu) | Gyógyszerészeti vegyületek | |
| GB201617454D0 (en) | Pharmaceutical compounds | |
| GB201704714D0 (en) | Pharmaceutical compounds | |
| GB201703881D0 (en) | Pharmaceutical compounds | |
| GB201612095D0 (en) | Pharmaceutical compounds | |
| IL269239A (en) | A pharmaceutical combination containing fonsimod | |
| GB201706806D0 (en) | Pharmaceutical compounds | |
| GB201703876D0 (en) | Pharmaceutical combinations | |
| ZA201805549B (en) | Syringe | |
| GB201704966D0 (en) | Pharmaceutical compounds | |
| GB201617871D0 (en) | Pharmaceutical compounds | |
| HRP20220427T8 (hr) | Farmaceutski spojevi | |
| GB201711704D0 (en) | Pharmaceutical compounds | |
| EP3431079C0 (en) | COMPRESSED | |
| GB201715316D0 (en) | Medicine Etc | |
| ZA201806493B (en) | Insecticidal tablet | |
| GB201717005D0 (en) | Pharmaceutical compounds | |
| GB201716001D0 (en) | EG tipex etc capsules |